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Abstract  
The past decades have seen advances in cancer treatments in terms of toxicity and side 
effects but progress in the treatment of advanced cancer has been modest. New drugs have 
emerged improving progression free survival but with little impact on overall survival, raising 
questions about the criteria on which to base decisions to grant marketing authorizations 
and about the authorization procedure itself. For decisions to be fair, transparent and 
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accountable, it is necessary to take account of the views of those with relevant expertise and 
experience.  
We conducted a Q-study to explore the views of a range of stakeholders in France, involving: 
54 patients (18 months after diagnosis); 50 members of the general population; 27 
oncologists; 19 healthcare decision makers; and 2 individuals from the pharmaceutical 
industry.  
Three viewpoints emerged, focussing on different dimensions entitled: I ‘Quality of life (QoL), 
opportunity cost and participative democracy’, II ‘QoL and patient-centeredness’ and III 
‘length of life’. Respondents from all groups were associated with each viewpoint with the 
exception of healthcare decision makers, who were only associated with the first one.  
Our results highlight the plurality in the views of stakeholders and emphasize the need for 
transparency in decision processes and the importance of re-evaluation of treatments for all 
three viewpoints. In the context of advanced cancer, our results suggest that QoL should be 
more prominent amongst authorization criteria, as it is a concern for two of the three 
viewpoints. 
N=237 
Key Words: Marketing authorization; Q-methodology, advanced cancer; efficacy criteria; 
societal perspectives; health policy 
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Introduction 
The past decades have seen advances in cancer treatments that have reduced toxicity and 
side effects. Despite these successes, there have been only modest advances in the 
treatment of advanced cancer [1,2]. Treatments are generally not curative, and survival 
benefit is usually measured in weeks or months [3,4]. Recently, new drugs have been 
developed which improve progression free survival but which have little impact on overall 
survival (such as Bevacizumab [5]). The emergence of such (typically high cost) drugs raises 
questions about the criteria that should be used in marketing authorization decisions and 
related ethical, economic and political issues. Should drugs for advanced cancer, which 
promise only modest extensions to life, be authorised for coverage from the public purse? 
 
Before a medicine can be sold it must have a license called a marketing authorization (MA).  
At the European level, once a drug has been recommended by the Committee for Medicinal 
Products for Human Use, MA is granted by the European Medical Agency (EMA). The decision 
to authorize medicines is based on three criteria relating to quality, safety and efficacy. The 
assessment of quality covers all aspects of the industrial production process. Safety is 
assessed on the basis of all research conducted during pre-clinical development. The efficacy 
criterion takes account of all of the clinical trials conducted on humans. Moreover, MA is 
granted if the new drug presents a benefit/risk ratio (established by the EMA) at least 
equivalent to the products already offered for sale – an additional ‘non-inferiority’ criterion 
(see [6] for a description of the procedure). These four criteria have been debated by 
physicians, with particular focus on efficacy (in relation to the choice of the relevant 
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endpoint) and non-inferiority [2,7–11]. In a second step, which is specific to each European 
Union member state, the coverage and the cost of the treatment are established.  
 
Davis (2015) has established a comprehensive review of the literature about the growing 
importance of the pharmaceuticalization in the context of advanced cancer, showing the 
increased use of aggressive, and sometimes inappropriate, drugs and questioning the 
relevancy of the MA process [4]. However, to our knowledge, no survey has directly 
exploring, the views of stakeholders in relation to the procedures used to determine MA. 
Their views are crucial if such decisions are to be fair, transparent and accountable, and if 
they are to reflect the views of those with relevant expertise and experience. This research 
contributes to the debate surrounding MA decisions by exploring the perspectives of all 
stakeholders in France: health care decision makers (concerned with resource allocation and 
the promotion of best practice); medical oncologists and cancer patients (the main actors in 
delivery of care and the beneficiaries of care); and the general population (potential patients 
and citizens who contribute to the funding of health services and medicines). Members of 
the pharmaceutical industry were also included in our sampling frame, as they are involved 
in the research and production of treatments, but recruitment was unsuccessful, as will be 
reported. Because all of these stakeholders occupy different positions in the process, they 
are likely to have different points of view and different priorities.  
This paper reports the findings of a study using Q methodology to elicit stakeholders’ 
viewpoints about the dimensions at stake in determining MA and about the processes used 





Q-methodology is designed to explore the nature of subjective viewpoints [12]. Developed 
by William Stephenson, Q methodology comprises qualitative and quantitative methods [13–
16] and has been applied in health related studies on topics such as understanding pain [17], 
the concept of quality of life [18], patients’ preferences toward the treatment of 
hypertension [19], informal caregivers’ attitudes [20] or eliciting the public’s views on health 
care resource allocation [16]. Q methodology was chosen because it allows the researcher to 
compare the accounts of respondents based on their response to a common set of 
propositions; it enables a holistic analysis [13,21]; it allows the emergence of counter 
intuitive results and it assists respondents in expressing their views by ordering a set of 
carefully selected statements. 
In Q studies respondents rank order a set of statements of opinion about a topic, on a grid, 
labelled according to a subjective dimension such as ‘agreement/disagreement’. This rank 
ordering, called a Q-sort, is obtained for each respondent. Factor analysis performed on the 
Q-sorts results in factors that represent shared viewpoints. In other words, in Q-
methodology, each factor obtained from the factor analysis represents a viewpoint shared by 
a group of respondents who have ordered the set of statements in a similar fashion. If each 
individual has a different viewpoint on the question, their Q-sorts will not correlate; if 
significant clusters of correlation exist, they can be factorized, described as common 
viewpoints, and individuals are mapped to a particular factor [20]. Each viewpoint is 
described by a distinct ordering of statements, which is interpreted holistically so that 
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statements are not interpreted in isolation, but collectively and relative to the position of the 
other statements. 
The statements (Q-set) 
Following a review of the literature, 21 semi-structured interviews were conducted with five 
members of the patients’ committee from the Institut Paoli-Calmettes (IPC) the regional 
cancer centre in Marseille; five medical oncologists from IPC and Institut Sainte Catherine in 
Avignon; three healthcare decision makers from HAS and the French National Cancer 
Institute; four members of the pharmaceutical industry; and four members of the general 
population. A first set of 54 candidate statements was extracted from the interview 
transcripts, [22] selected because they represented distinct statements of opinion in relation 
to the topic of study. To help us reducing the set of statements, this first set was submitted to 
the medical oncologists and patients who had been interviewed, and to five (new) members 
of the general population. A final Q-set of 34 statements was selected (and reworded in 
accordance with the comments) in order to cover the range of issues at stake, that could be 
classified onto four dimensions (See table 2 for a list of the statements): quality of life (QoL) 
and side effects; clinical gain (duration of the life extension); cost of treatment and MA 
procedure (see table A1 in appendix for the links between statements and the four 
dimensions). The final Q-set was pilot tested with the three co-authors from IPC (DG, AG, 
PV), 5 new members of the general population and four (new) patients from IPC. We did not 
identify any concerns about comprehension of statements from our pilot study. 
Respondents (P-set) 
Selection of respondents in Q studies has much in common with qualitative, purposive 
sampling techniques and respondents are selected who will have strong views, relevant 
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experiences and different viewpoints from one another. In this study participants were 
recruited from 5 groups: non metastatic cancer patients, members of the general population, 
medical oncologists, health decision makers, and representatives from the pharmaceutical 
industry. As a guide to the size of the P set, Brown suggests that 40-60 respondents is more 
than likely adequate [23]. We have chosen a relatively large sample (in Q terms) to retain the 
option to analyze the data for each respondent subgroup as well as pooling the data for the 
whole sample. On examination all the viewpoints elicited by group are highly correlated with 
one of the viewpoint from the pooled data (see figure A1 in appendix), hence we present 
results based from the whole sample. 
The resulting sample includes more patients and members of the general population than 
oncologist and health care decision makers. We anticipated that professionals would have 
more ‘established’ viewpoints, ones which they may have previously articulated, and so 
(partly to reduce the time and cost of data collection) we aimed to collect 15 to 20 Q-sorts 
from medical oncologists and from health decision makers, 10 to 15 from members of the 
pharmaceutical industry and 50 from patients and members of the general population2: 
 54 patients (PA), in remission at 18 months of their diagnosis were recruited at IPC. Non-
metastatic cancer patients were identified, by the clinical research and innovation 
department, from consultation lists. They were informed of the subject and the conditions 
of the study by mail. If they did not wish to participate, they could indicate non-consent 
by sending a reply in a pre-paid envelope, otherwise they were met by a psychologist on 
the day of their consultation.  
                                                     
2
 It is worth considering whether this would have an effect on the factor solution. In Q methodology, once 
factors are identified, subsequent similar Q-sorts serve only to substantiate the account represented by that 
factor. For that reason, we don’t expect the factor solution is altered significantly by this sampling strategy, 
unless we have inadvertently, systematically excluded a group of respondents with a different viewpoint... 
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 50 members of the general population (POP) were recruited in a municipal library (named 
Alcazar, and located in the center of Marseille, France, which allowed us to recruit people 
belonging to a large sample of different socio-professionals categories). Participants were 
informed of the research using flyers and a poster at the entrance of the library asking for 
volunteers to participate.  
 27 oncologists (ON) were recruited via the oncologists’ directory and the Centres Against 
Cancer websites.  
 19 health decision makers (HDM) from public organisations with some responsibility for 
allocation of resources and promotion of good practice (regional health agencies and the 
HAS). 
 Only 2 representatives of the pharmaceutical industry (IND) agreed to participate despite 
asking the LEEM (the French Pharmaceutical Companies Association) to recruit 
respondents on our behalf. 
The professionals (ON, HDM and IND) were sent an email informing them of the research and 
providing them with a link to the online questionnaire. 
Q-sort administration 
The Q-sort was administered face to face using a computer interface for PA and POP, and 
online for the professionals. No remuneration was offered to any of the participants to the 
survey.  
Q-sorts require participants to order and prioritize each statement in relation to every other 
statement. First, respondents were asked to sort the statements, presented to them in 
random order, into three piles: agree, disagree and neutral. Respondents were then guided 
through a process of ranking the statements, onto a response grid, from the ones they agree 
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with the most to the ones they disagree with the most. The grid was designed in a quasi-
normal shape, with a fixed number of items placed under each scale point (see figure 1). The 
two statements they agreed with the most were placed under (+4) and the two they 
disagreed with the most were placed under (-4), and so on, working towards the centre of 
the grid, until all statements were placed. Once the sort was complete, respondents were 
invited to examine and adjust it if they wished. They were then asked to provide open-ended 
comments to explain their rationale for the choice of the four statements placed at the 
extremes. 
We used FlashQ (http://www.hackert.biz/flashq/home/) a dedicated online Q-sorting tool.  
Data-analysis 
The Q-sorts were analyzed using a dedicated software package PQMethod 2.35 which 
facilitates Q factor analysis and interpretation (see the PQ manual for details 
http://schmolck.userweb.mwn.de/qmethod/downpqwin.htm). The first step in Q factor 
analysis is the calculation of a correlation matrix, which presents the degree of similarity 
between individuals’ Q-sorts. The objective of Q factor analysis is to identify a limited 
number of similar ways in which respondents have completed their Q-sorts (i.e. rank ordered 
the statements). Q-sorts with higher loadings are given more weight in the idealized Q-sort 
since they better exemplify the factor. In this way each factor (representing a shared 
viewpoint) is represented by a single, idealised Q-sort [18]. This idealized Q-sort represents 
the Q-sort of a person who would be correlated 100 percent with that factor. Confounded Q-
sorts (i.e. those with significant loading on more than one factor) were not used in the 
calculation of the idealized Q-sort (see table A1 in appendix for more details) [12,23]. 
Interpretation of each viewpoint is based on the idealized Q-sorts together with respondents’ 
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comments on their Q-sorts. The salient statements, at the extreme poles of the grid, are 
important to interpretation as are significantly ‘distinguishing statements’ that are placed 
differently between factors. The interpretation is not made statement by statement, but 
rather aims to present a holistic interpretation of each viewpoint. 
There are several approaches to factor extraction and rotation used by Q methodologists, 
and debate about which is more appropriate [12,24]. The objective of the rotation is mainly 
to facilitate interpretation of the factors [25]. Manual rotation allows the analyst to examine 
the data from a graphical perspective, not to alter the correlations between Q-sorts, but to 
examine the relationships between Q-sorts from different angles. Varimax rotation is also 
used by Q methodologists; often because this is the statistical procedure most often used in 
standard factor analysis and maximizes the variance explained by the rotated factor solution 
[12]. The two rotation methods have advantages and disadvantages. In this analysis several 
combinations of extraction (centroid or principal component analysis) and rotation (manual 
or varimax) were examined and compared. 
Manual rotation is generally guided by ‘hunches’ that emerge about the data, the subject 
matter or about participants’ accounts [26] or may be guided by theoretical reasoning [27]. 
Where several solutions are available to the analyst, selection of a ‘best’ solution is often an 
iterative process, following up on hunches and consulting both qualitative and quantitative 
information [26]. In this case we were interested in examining the patterning of different 
respondent types across factors and, in particular, to manually rotate factors in relation to 
respondents in the smallest group (from the pharmaceutical industry) to examine the factors 
from that perspective. Because this group was small we expected that the account might be 
lost in a purely statistical solution, which was the case. Although one IND, loaded on the 
second factor in the unrotated matrix, it was no longer the case with the centroid varimax 
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solution. Following graphical examination of the factors in relation to all of our respondent 
groups we conducted a fairly straightforward rotation in an attempt to maximize the number 
of uniquely correlated (“pure”) Q-sorts, preserving the loading of the IND Q-sort. The best 
solution was obtained by rotating factors F1 and F2 -25 degrees, and rotated factors F1 and 
F3 +5 degrees. To test the robustness of our results, we compared the results of our manually 
rotated solution with the solution generated by centroid followed by a varimax rotation, 
which revealed statistical comparable results3. 
We then report the solution of principal component analysis followed by manual rotation 
which was preferred on grounds of interpretability and consistency with respondents’ 
accounts (including viewpoints elicited by group - see Fig. A1) and secondly because it 
allowed the most respondents Q sorts to be purely associated with a single factor (in other 
words it was the most interpretable solution with the most pure loadings) without sacrificing 
the variance explained compared with the varimax alternative. 
Results 
The final participant sample was composed of 146 participants. Q-sorts from two PA and four 
POP were excluded, because they stated that the rank given to one of the statements at the 
extreme (+/- 4) was positioned in error. The sample consisted of 72 women and 74 men with 
mean age 49 years (see Table 1 for a description of the sample). 
Our data supported a maximum of a four-factor solution, on the basis that each factor should 
include at least two non-confounded loaders (individuals with significant correlation with 
                                                     
3
 The correlation matrix shows that: PCA F1 is correlated with CEN F1 (0.94), PCA F2 is correlated with CEN F3 
(0.71) and PCA F3 is correlated with CEN F2 (0.84). Moreover, the manual rotation accounted for more defining 
variables (97 vs 87), with similar percentage of explained variance (44% vs 43%) and resulted in lower 
correlation coefficient between factors. 
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only one factor and not the others). As the four factor solution added only 3% to the total 
variance explained (47% vs. 44%) and presented less distinction in the content of each factors 
(higher correlation coefficients between factors, see. figure 2) the three-factor solution was 
selected. With this three viewpoint solution 97 respondents were uniquely associated with a 
single viewpoint and 16 respondents were confounded), the 33 remaining respondents were 
not correlated with any of the three factors (Table A2). In what follows, we present a 
description of the respondents and then we describe each viewpoint they are associated 
with. Rankings of the statements are provided in abbreviated form, (s31 +4) means that 
statement 31 is ranked in the +4 position (agreed the most) and (s29 -4) means that 
statement 29 is ranked in the -4 position (disagreed the most) for the viewpoint in question. 
The statements and respondents’ comments have been translated from French and quotes 
are provided to illustrate or clarify interpretations (respondent ID number/ type of 
participant is indicated). 
Viewpoint 1: Quality of life, opportunity cost and participative democracy  
Seventy-two respondents’ Q-sorts were significantly correlated with viewpoint 1: 16 HDM, 18 
ON, 13 PA, 25 POP.  
This first viewpoint regards QoL as more important than length of life (s27 -4, s29 -4, s18 -3, 
s33 +3, s22 +1), and an effective treatment is one which allows the patient to live a life 
comparable to their life before the disease (s2 +2, s23 +1). So, for the HDM83 “Quality of life 
must be included as a major criterion, especially for a drug that improves survival very little”. 
The emphasis on QoL is coupled with a concern about MA procedures. For viewpoint 1, as for 
the two others, it is important that outcomes of the MA committee are transparent and 
made public (s31 +4) and that treatments are regularly re-evaluated after their launch on the 
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market in order to judge their efficacy and their tolerance in general practice (s28 +4). PA36 
states that “Transparency is essential in democracy”. There is some support in this account 
for granting temporary authorization, and delivering definitive MA only after the treatment 
has been proven over time and among different populations (s11 +2). The procedures of the 
MA committee should also take into account the views of patients through a patient 
representative (s6 +3), patients’ reports of the impact of side effects on their everyday life 
(s34 +3), and to a lesser extent the views of the general public (s7 +2). This viewpoint is 
hence concerned with a form of participative democracy which takes account of the views of 
those people directly affected by decisions as well as the points of view of citizens.  
Lastly, the position taken on the cost of treatments distinguishes this viewpoint from the two 
others. Participants associated with this viewpoint believe that MA should also take into 
account the impact of coverage decisions for society more broadly and the benefits of 
treatments should be weighed up against alternative uses of resources (s19 -3, s4 -2, s17 -2). 
In other words the opportunity cost for society, and not only the needs of the patients, 
should be considered as part of the MA procedure (s26 +2). As such the MA committee takes 
the role of agents of the citizen. This is an important distinction, which we return to in the 
discussion. 
Viewpoint 2: Quality of life and patient-centredness 
Eighteen respondents were significantly associated with this viewpoint: 3 ON, 11 PA, 3 POP, 1 
IND.  
The core of this viewpoint is patient-centred. Like viewpoint I, QoL is of greater concern than 
length of life (s18 -4, s27 -3, s29 -3, s32 +2, s33+2) as explained by PA82, “On the contrary, I 
think that in case of an incurable cancer, the point is the quality of the remaining life”. In 
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contrast with viewpoint 1, importance is placed on life expectancy gains. Cost, on the other 
hand, is not a central issue for viewpoint 2. Consider, for example, the position of statement 
14 at +4 (-1 and 0 for viewpoints 1 and 3 respectively), summed up by the comments of one 
patient, “Life has no price. Society must contribute to cost of care” (PA108). The cost of 
treatments to society is not an issue which should be considered during the MA procedure 
(s26 -4) and this view is evident in the placing of all statements describing a trade-off 
between a clinical gain and cost of treatments (s14 +4, s4 +2, s17 +2). ON60 “the cost of 
drugs should not affect the improvement of quality of care […] however, we have to be 
reasonable”. 
As in the previous viewpoint, MA procedures should include treatment re-evaluation (s28 +4) 
and the need for transparency (s31 +3) is emphasized. Patients’ reports of the impact of side 
effects on their everyday life is seen as important (s34 +3), but views about the inclusion of a 
patient representative as part of the MA committee are more equivocal (s6 +1) and 
considering the view of the general population is not relevant (s7 -2). Lastly, temporary MA is 
of some appeal for this viewpoint as a means to accelerate access to promising treatments 
(s24 +3) but not as a means to impose restrictions on a definitive MA (s11 0). 
Viewpoint 3: Length of life 
Eight respondents loaded significantly on this viewpoint: 4 ON, 2 PA, 1 POP. 
This viewpoint is characterized by the priority given to any treatments that result in life 
extension and a refusal to define a minimum threshold in terms of survival gain required for 
MA (s8 -4, s10 -4, s9 -3, s15 -2, s16 -2). Even a gain of 1 month is considered sufficient (s5 +2) 
regardless of the cost to society (s19 0). POP28 commented that, “survival gain should not be 
rigid criteria to grant MA” and ON61 claimed, “Patients prefer benefiting from a treatment 
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even if the gain in expected survival is small. In this case 6 months is an average gain, some 
patients will benefit from longer survival, for instance 2 years!”. There is also importance 
placed on increasing the range of available treatments, especially when few treatments are 
available (s25 +4) and to the rapidity in access to the new treatments, using temporary MA 
(s24 +3). 
In contrast with the two other viewpoints, QoL does not prevail over length of life (s33 -3, 
s23 -2), and a gain in survival is preferred even if it implies a decrement in QoL (s12 +2, s18 
+1, s29 +1). A treatment that decreases the risk of disease progression is appropriate even if 
it has negative impact on family, social and professional life (s30 +3), on thinking skills, 
concentration and memory –s3 +1). The idea that an effective treatment is a treatment 
which allows the patient to live a comparable life as the one before the disease is seen as 
unrealistic (s2 -3). 
Although views concerning transparency (s31 +4) and re-evaluation (s28 +3) are shared with 
viewpoints 1 and 2, taking into account the patient’s point of view during the MA process is 
not so important for this third viewpoint (s34 0, s6 -1), and including a representative of the 
public in MA process is not relevant (s7 -2). Lastly, the question of treatment cost is not a 
concern in this viewpoint and none of the statements concerned with cost were placed at 
the extremes of the grid (+/- 4 and 3). 
Discussion 
The criteria used to make decisions to grant MA for medicines raises issues of ethical, 
political and economic debate, especially in the context of drugs for advanced cancer. We 
contribute to this debate with research based on the opinions of 146 stakeholders: non 
metastatic cancer patients at 18 months after their diagnosis, oncologists, health users 
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(citizens) and health decision makers. All of these stakeholders have different roles, 
knowledge, experiences and interests, and thus potentially have different points of view. To 
our knowledge this is the first survey eliciting the views of a large range of stakeholders, 
including a substantial cancer patient group [28]. We have shown not only that different 
views exist, but also how they emerge from these different stakeholder groups, revealing 
that respondents’ membership or allegiance with groups as defined here is not a good 
predictor of point of view, but that the views of HDMs are clustered around one viewpoint 
and not the others. Although we hoped to include the views of those employed in the 
pharmaceutical industry, only two people agreed to participate (of the 10 to 15 expected). 
It’s difficult to explain the reason for their refusal to participate, despite our attempts to 
recruit respondents through the LEEM. One explanation could be a sensitivity amongst 
potential respondents with respect to the image of the pharmaceutical industry because of 
some recent cases [29,30].  
Q Methodology provides a framework for enabling respondents to rank a large number of 
statements, and thereby express subjective opinions about complex issues. It not only helps 
reveal how respondents feel about the issues raised by a topic but also identifies the relative 
significance that they attach to those issues. An advantage of this approach over more 
conventional qualitative methods is the capacity to present a set of statements to all 
respondents to consider. Using other methods it is possible that some dimensions may be 
missed because each sub-population is confronted only with their own perceptions of the 
topic [16,22]. This is illustrated by contrasting our Q study findings with the findings of a 
previous qualitative phase of research, where we showed variability of the significations 
associated with the criteria of efficiency of cancer treatments according to the sub 
populations [16]. 
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Whilst Q studies are effective methods for eliciting and describing shared viewpoints on a 
subject, it is not a means of generating information about the proportion of population who 
agree with these views [15,22]. Three viewpoints emerged from our analysis: the first 
concerned with quality of life, opportunity cost and participative democracy; the second 
focussed on quality of life and patient-centredness and the third centrally concerned with 
length of life. Given the populations surveyed it is perhaps unsurprising that elements of 
these three viewpoint emerged. However, the distribution of ‘respondent-types’ across the 
three viewpoints is interesting. The QoL, opportunity cost and participative democracy 
viewpoint is held by respondents in all four sub-populations. Viewpoints two and three are 
shared by oncologists, patients and the public, no health decision makers loaded significantly 
on these viewpoints. Thus, whilst the views of experts/professionals were not misaligned 
with the views of patients and the general population, health care decision makers are 
closely aligned only with one viewpoint. Oncologists and patients, who might be expected to 
have strong opinions, were associated with all three viewpoints. Our failure to recruit 
members of the pharmaceutical industry means that we are unable to draw any conclusions 
about how their views align with the views of others, but we have retained two industry 
respondents’ data in our analysis, one of whom was associated with the second viewpoint.   
There may be some limitations in our methods that relate to the selection of the statements. 
In Q studies it is expected that respondents who are associated with different viewpoints 
might interpret different statements in different ways. Wording is often more loosely 
constructed than in survey research, since it is the collection of all statements in a specific 
order that reveal the different ways of seeing an issue, and which we attend to when 
interpreting viewpoints. Despite efforts to cover the range of issues, and to find balance such 
that respondents with different views on the topic can find a means to express those views 
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through the Q set, some statements might be difficult to understand, might overlap too 
much or could limit respondents expression of their views in some ways that we are not 
aware of. Our pilot work indicated that statements were well understood. 
Turning to the narratives, and what they might mean for policy and practice, issues of 
consensus were identified across the viewpoints. There was agreement about the 
importance of re-evaluating treatments after their launch on the market, to judge their 
efficiency and their tolerance in general practice (s28: +4 +4 +3). The importance placed on 
transparency (concerning the outputs of the MA committee and the wish to make them 
public) was also a major concern across all viewpoint (s31: +4 +3 +4). Our findings suggest 
that simply making the MA committee reports publicly available (as they have been since 
2006) is not sufficient. ON79 expressed a “wish to better understand the reasons of an 
acceptance or a refusal of a MA”. More widely, this strong interest in transparency might be 
related to the need to restore confidence as illustrated by the so-called French Sunshine Act 
(Decree n° 2013-414 devoted to bring transparency [32]) and to wider pressure for a more 
ethical economy.  
The beginnings of a response, balancing the need for rapid access to drugs for new 
indications and the lack of information on their benefit-risk ratio, has been proposed through 
the “temporary recommendations for use” (TRUs; decree number 2012-743) [33], which, as 
shown by our results, is consistent with the expectations of ON, PA and POP from viewpoints 
2 & 3. This decree aims to regulate off-label drug use, but could potentially be extended to all 
new drugs, as hoped for by all stakeholders associated with viewpoint 1. 
 
19 
Applications for MA are evaluated according to quality, safety and efficacy criteria, that is to 
say, according to “hard”, scientific criteria. Our survey has shown, in the context of advanced 
cancer, the importance attached to QoL. Because it is essentially subjective and 
multidimensional [18] QoL is more difficult to evaluate. QoL is considered essential by 
respondents associated with viewpoint 1 “QoL, opportunity cost and participative 
democracy” and viewpoint 2 “QoL and patient-centred” but not by viewpoint 3 “the length 
of life-centred”. However, it is interesting to note that some professionals stated, during the 
qualitative step, that extending length of life automatically implied an improvement in QoL. 
This result raises questions about the appropriate efficacy criteria to be considered in 
authorising a new drug for advanced cancer. Steer et al. (2001) argue that in patients with 
advanced disease therapy is not usually curative and, as such, endpoints associated with 
palliative care are more relevant. This turns the focus towards quality of life (rather than 
objective measures of, for example, tumour response rate and its duration) as a more 
relevant endpoint. This result is also in line with research by Silvestri et al. (1998) who have 
shown that a higher proportion of non-small lung cancer patients choose chemotherapy for a 
reduction of symptoms, without prolonging life, rather than for a survival benefit [34]. It is 
important to consider means to better take account of QoL as an endpoint during the MA 
process for medicines for advanced cancer. One step could be to focus on time to tumor 
progression free survival if a link between QoL and progression free survival is confirmed [8]. 
Another approach could be to define more specific criteria for instance according to the 
length of expected median survival time [2].  
Beyond these criteria for authorization, the new product must have a benefit risk ratio at 
least equivalent to the products already on the market. It is notable in our research that one 
of the consensus statements (s1: -1 -1 -1) indicates that respondents were rather against (or 
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neutral) about this « non inferiority » criteria, which is illustrated by the comment of HDM88. 
“There is no interest to increase the number of options available, if there is no therapeutic 
gain”. The requirement to demonstrate added value for all new drugs, or at least to 
demonstrate that benefits outweigh side effects has already been discussed in the literature 
[29,35]. 
 
One issue that distinguishes the viewpoints from each other is whether the cost of 
treatments should be considered during the MA procedure (s26: +2 -4 -1). Although from a 
pragmatic perspective incorporating ‘price’ as part of the MA procedure would be difficult at 
the European level (at least for the moment because of differences between countries in 
approaches to the funding and provision of health care) the question remains important. The 
issue of resource allocation and priority setting is addressed by HDM40 “Need to include 
public health ethics and not individual ethics. When a drug is on the market, the physician has 
to propose it to the patient, to inform him of the benefits and side effects and it is not his job 
to take cost for society into account. The cost that society is prepared to incur for a year 
adjusted on quality of life must be set upstream.” This point is central for the viewpoint 1 
“QoL, opportunity cost and participative democracy” with the rejection of every statement 
supporting the provision of treatments which generate health gains whatever the cost for the 
society as declared by POP60 “It’s crucial to calculate the relationship between the benefit of 
the drug and its cost for society, i.e. the cost of survival”. The fact that the two other 
viewpoints do not considered the question of cost may not necessarily mean they reject the 
reality of a budget constraint, but perhaps that they do not prioritise this dimension as much 
as the others. In a Q study in the UK, investigating the relative value of life extension for 
people with terminal illnesses, a factor that rejects cost as a criteria has also be identified 
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[28]. In their discussion of their findings McHugh et al. (2015) argue that respondents did not 
challenge the reality of a fixed budget, but thought that life-extending treatments for 
patients with terminal illnesses would be affordable if government distributed resources 
more appropriately “For example, some interview respondents suggested reallocating 
resources from other areas of government spending (e.g. defence), cutting waste in the NHS, 
or greater regulation of pharmaceutical industry pricing”p13. 
 
Conclusion 
Our results emphasize the need for transparency and re-evaluation of treatments after they 
have received MA. These two issues were important to respondents associated with all the 
three points of view, and views expressed by all categories of respondent.  
Our findings also suggest that, in the context of advanced cancer, QoL is important, although 
not supported by viewpoint 3, which is primarily concerned with survival gain, showing the 
complexity of the topic and the need to consider the diversity found in subjective opinion on 
this topic as well as issues of consensus.  
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Table 1: Sample description (n=146) 
 
F1 F2 F3 loaders Total 
 
 













Population Health decision makers 16 22 0 0 0 0 16 16 19 13 
Oncologists 18 25 3 17 5 63 26 27 27 19 
Cancer patients 13 18 11 61 2 25 26 27 52 36 
General population 25 35 3 17 1 13 29 30 46 32 
Members of the 
pharmaceutical industry 
0 0 1 6 0 0 1 1 2 1 
Sociodemographic characteristics 
           
Age (mean, sd) 48,5 14,8 54,2 15,1 49,8 13,2 48,3 16,8 49,2 15,4 
Gender Female 33 46 10 56 2 25 45 46 72 49 
Male 39 54 8 44 6 75 53 54 74 51 
living with a partner 
 
41 57 13 72 5 63 59 60 91 62 
Having children 
 
50 69 15 83 8 100 73 74 107 75 
Study level Less or equal to a level 12 17 8 44 2 25 22 22 46 32 
High national diploma, 
diploma of higher 
education 
8 11 2 11 0 0 10 10 15 10 
Bachelor degree, Master 
degree 
12 17 2 11 0 0 14 14 20 14 
Advanced studies and PhD 40 56 6 33 5 63 51 52 64 44 
 Missing value 








Professional status Employed 44 61 10 56 7 88 61 62 81 55 
Unemployed 6 8 0 0 0 0 6 6 9 6 
Students 5 7 1 6 0 0 6 6 12 8 
Retired 15 21 7 39 1 13 23 23 38 26 
 Invalidity 0 0 0 0 0 0 0 0 3 2 
 Missing value 2 






           
Has already been treated for a cancer 
 
19 26 11 61 2 25 32 33 59 41 
Has already been treated for another serious illness 7 10 2 11 2 25 11 11 15 11 
Has a close relative who has (had) a cancer 57 79 14 19 8 100 79 81 120 83 
Has been confronted with the death of a close relative because of 
cancer 
55 76 11 61 6 75 72 73 106 73 
Length of the questionnaire (mean, sd) 31,1 15,6 38,2 13,0 29,2 19,3 32,2 15,6 34,1 15,0 
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Table 2: Factor array (statements and their ranking for each factor) 
 F1 F2 F3 
1. It’s sufficient for a treatment to be at least as effective as the best available treatment, for receiving MA1. -1 -1 -1 
2. An effective treatment is a treatment which allows the patient to live a comparable life as the one before the disease.  2 1 -3 
3. In my view a treatment that reduces the risk of disease progression must receive MA even if it temporarily affects thinking skills, 
concentration and memory. 
-1 1 1 
4. If a treatment represents real medical progress, it is legitimate that its cost for the society is very high. -2 2 0 
5. For an illness where the average lifespan without treatment is 6 months, a survival gain of 1 month is a sufficient benefit for receiving a 
MA. 
-3 -2 2 
6 It’s important that patients are represented and that their opinions are taken into account in MA committee deliberations.  3 1 -1 
7. It’s important that members of the general population are represented and that their views on treatment benefits are taken into account in 
MA committee deliberation 
 2 -2 -2 
8. If standard treatment results in an average life expectancy of 1 year, a new treatment must produce a survival gain of at least 6 months to 
receive MA. 
0 -3 -4 
9. For illnesses where half of the patients will benefit from the treatment, a new treatment must produce a survival gain of at least 6 months 
to receive a MA. 
0 0 -3 
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10. If standard treatment results in an average life expectancy of 2 years, a new treatment must produce a survival gain of at least 6 months to 
receive a MA. 
0 0 -4 
11. It would be better to give temporary MA and delivering definitive MA only after the treatment has been proven over time and among 
different populations. 
2 0 1 
12. If standard treatment results in an average life expectancy of 2 years, and a new treatment gives patients an extra six months but worse 
side effects, the new treatment must receive a MA. 
0 -1 2 
13. Survival is a major criterion in the evaluation of cancer treatments: a gain of two months is not enough for a treatment to receive a MA.  -2 -2 2 
14. If a new treatment can provide clinical benefits to many patients, then it does not matter if its cost to society is higher than for the 
standard treatment. 
-1 4 0 
15. A treatment must receive a MA if, compared to the standard treatment, it increases the number of patients still alive 1 year after diagnosis 
by at least 10 %. 
1 0 -2 
16. A treatment with significant side effects must receive a MA if it prolongs lifespan of at least 1 year. -1 -1 -2 
17. If a new treatment increases survival time from 24 to 34 months but the cost is multiplied by 50 it must be given MA. -2 2 1 
18. In the case of a cancer that cannot be cured, I think it is important to prioritize treatments that allow people to live as long as possible 
even if it implies an alteration of QoL. 
-3 -4 1 
19. If a treatment can prolong lifespan, even by one month, it should be given MA whatever its cost to society. -3 -1 0 
20. In my view, a treatment that limits the risk of disease progression must receive MA even if it has negative consequences on well-being -2 -2 0 
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and autonomy. 
21. In case of cancer with little chance of cure, a treatment which reduces pain must receive MA even if it affects patients’ abilities to reflect, 
concentrate and remember. 
1 1 -1 
22. A more expensive treatment which is not more effective in terms of life extension than the standard treatment, but which protects QoL 
must receive a MA. 
1 1 2 
23. If a treatment which was intended to prolong my life prevented me from living a normal life, I would prefer not to take it. 1 0 -2 
24. In case of promising treatments for which there is a lack of evidence, it’s important to give temporary MA in order to make them 
accessible quickly. 
1 3 3 
25. A treatment that provides a slight benefit for an illness for which few treatments are available, must receive MA. 0 -1 4 
26. The treatment cost for society has to be considered during the MA procedure. 2 -4 -1 
27. In my view, compared to the gain in survival, QoL is a secondary endpoint. -4 -3 -1 
28. Treatments must be regularly re-evaluated after their launch on the market, to judge their efficacy and their tolerance in general practice. 4 4 3 
29. I would be prepared to accept a treatment with significant side effects, even if the chances that it prolongs my life are low. -4 -3 1 
30. I think that a treatment must receive MA if it limits the risk of disease progression, even if it has negative impact on family, social and 
professional life. 
-1 0 3 
31. It is important that outputs of the MA committee are transparent and made public. 4 3 4 
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32. If a treatment doesn’t cure but allows the patients to continue their activities, then it should receive a MA, whatever the cost. 0 2 0 
33. I would prefer a treatment targeted on pain reduction and comfort, even if it means not living longer. 3 2 -3 
34. Patients reports of the impact of side effects on their everyday life must be taken into account during the MA procedure. 3 3 0 
 
 
